Bruker (BRKR) CEO Receives RSUs and $33.52 Strike Options on 08/15/2025
Rhea-AI Filing Summary
Bruker Corporation insider grant to its President & CEO. The filing reports that on 08/15/2025 Burkhard Prause, listed as President & CEO, was granted 5,298 Restricted Stock Units (RSUs) and 5,008 stock options with an exercise price of $33.52. The RSUs vest in four equal annual installments beginning on the first anniversary of the 08/15/2025 grant date, and the options vest on the same four-year annual schedule with an exercisable date beginning 08/15/2026 and expiration on 08/15/2035. After the RSU grant the reporting person beneficially owned 25,158 shares. The form is signed by an attorney-in-fact on 08/19/2025.
Positive
- Grant disclosed: 5,298 Restricted Stock Units and 5,008 stock options were clearly reported for 08/15/2025
- Vesting schedule disclosed: RSUs and options vest in equal installments on each of the first four anniversaries of 08/15/2025
- Options terms provided: Exercise price of $33.52, first exercisable 08/15/2026, expiration 08/15/2035
- Post-transaction ownership: Reporting person beneficially owned 25,158 shares following the RSU grant
Negative
- None.
Insights
TL;DR: Routine equity-based compensation granted to the CEO with four-year vesting, common for retention and alignment.
The report documents standard executive equity awards: 5,298 RSUs and 5,008 options at a $33.52 strike, each vesting in four equal annual tranches. The options become first exercisable on 08/15/2026 and expire 08/15/2035. Such grants are typical for linking executive pay to company performance over multiple years. The filing provides clear vesting and ownership figures but contains no commentary on grant rationale or performance conditions.
TL;DR: Material details of award size and schedule are disclosed, but no performance metrics are included.
The Form 4 discloses precise quantities and vesting terms: 5,298 RSUs and 5,008 stock options at $33.52, vesting in equal annual installments over four years. The disclosure allows calculation of potential dilution and timing of potential insider sales, but it does not state whether awards are time-based only or tied to specific performance targets.